IO NewsWire

August 23, 2010 07:30 ET

(OTCBB: ACCP) FDA Approved MuGard Targets $1 Billion Market

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

NEW YORK, NY--(Marketwire - August 23, 2010) -  Access Pharmaceuticals (OTCBB: ACCP) CEO Jeffrey Davis discusses MuGards' recent FDA approval with OutsideIn Research.

Access Pharmaceuticals is taking aim at the estimated one billion dollar market in the treatment of oral mucositis (OM). OM is a painful ulceration of the mucous membranes lining the digestive tract. OM is commonly brought on by chemotherapy and radiation treatments administered to cancer patients. Estimates are 90% of all patients undergoing radiation treatment and 40% receiving chemotherapy get mucositis.

MuGard has a lower cost per patient, and is easier to administer compared with other gel based treatments on the market. Zacks Equity Research estimates MuGard sales will see a peak of $300 million and capture a quarter of the OM treatment market. As MuGard gains acceptance in the medical communities, Access Pharmaceuticals should see a significant rise in bottom line profits.

To view the entire interview with OutsideIn Research please visit

Other active stocks are King Pharmaceuticals (NYSE: KG) Genzyme Corp (NASDAQ: GENZ) and Cephalon Inc (NASDAQ: CEPH)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information